[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cervical-squamous-cell-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cervical-squamous-cell-cancer":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100658072","phase-2-clinical-investigator-initiated-trial-iit-of-pd-l1-targeted-radionuclide-probes-100658072",false,"NCT07848243","Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes","Inclusion Criteria:\n\n1. Age \\>18 years old, ECOG score 0 or 1;\n2. subjects with pathologically confirmed solid tumors (lung cancer, cervical cancer, melanoma, breast cancer, gastrointestinal tumor, etc.), recent recurrence or suspected recurrence of previous solid tumors;\n3. There was at least one measurable target lesion according to RECIST1.1 criteria;\n4. Predicted survival time ≥12 weeks;\n5. Blood routine, liver and kidney function meet the following standards: see the study protocol for specific requirements;\n6. Women must be using an effective contraceptive method (effective contraception means sterilization, intrauterine hormonal devices, condoms, contraceptives\u002Fpills, abstinence, or partner's removal of the vas deferentia) during the study and for 6 months after the study; Men should consent to subjects who must use contraception during the study period and for 6 months after the end of the study period;\n7. Subjects can fully understand and voluntarily participate in this experiment, and sign an informed consent. Compliance was good.\n\nExclusion Criteria:\n\n1. Severe abnormal liver and kidney function.\n2. Pre-pregnancy, pregnant and lactating women.\n3. Unable to lie flat for half an hour.\n4. Refusal to be a clinical investigator.\n5. Claustrophobia or other mental illness.\n6. Known allergy to the investigational drug or its excipients in the study treatment; Other circumstances considered by the investigator to be inappropriate for trial participation.","ALL","18 Years",{"count":18,"type":19},50,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","\\[18F\\]F-PDL1-3 molecular probe was used to detect the expression of PD-L1 in primary and metastatic tumors of patients with solid tumors. The heterogeneity of PD-L1 expression in the same lesion and different lesions was further evaluated, and the changes of PD-L1 expression in the course of the disease were observed. This method is helpful for the screening of patients with solid tumors with high PD-L1 expression, efficacy monitoring, and early warning of drug resistance and\u002For recurrence or metastasis, and ultimately achieve individualized targeted therapy of tumors",[25,26,27,28,29],"Lung Cancer (NSCLC)","Cervical Squamous Cell Cancer","Melanoma (Skin Cancer)","Breast Cancer","Gastrointestinal Cancers",[31,32],"Radioactive medicine","De novo design","RECRUITING","2026-09-23",{"date":36,"type":37},"2026-09-29","ACTUAL",{"date":39,"type":37},"2026-02-01",{"date":41,"type":19},"2027-12-31",{"name":43,"class":44},"Peking University Cancer Hospital & Institute","OTHER"]